ReviewBrain : a journal of neurology2018
Can neuroimaging predict dementia in Parkinson's disease?
Review in Brain : a journal of neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 75 citations in OpenAlex.
- Orthostatic hypotension in dementia with Lewy bodies: a meta-analysis of prospective studies.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2023Pooled it
- Supplementary motor area microstructure defines the extent of gait impairment in Parkinson's disease.NPJ Parkinson's disease · 2025Article
- Cortical hypometabolism in Parkinson's disease is linked to cholinergic basal forebrain atrophy.Molecular psychiatry · 2025Article
- Leveraging explainable artificial intelligence with ensemble of deep learning model for dementia prediction to enhance clinical decision support systems.Scientific reports · 2025Article
- Imaging biomarkers of cortical neurodegeneration underlying cognitive impairment in Parkinson's disease.European journal of nuclear medicine and molecular imaging · 2025Article
- Subregional analysis of the amygdala, thalamus, and hypothalamus at the pre-decline stage in Parkinson's disease with later cognitive impairment.Frontiers in aging neuroscience · 2025Article
- Article
- Review
- The basal forebrain cholinergic system as target for cell replacement therapy in Parkinson's disease.Brain : a journal of neurology · 2024Review
- Plasma miR-203a-3p as a Novel Predictor of Dementia in Patients with Parkinson's Disease.International journal of molecular sciences · 2024Article
- Longitudinal Associations of Magnetic Susceptibility with Clinical Severity in Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2024Article
- Neuroimaging and plasma evidence of early white matter loss in Parkinson's disease with poor outcomes.Brain communications · 2024Article
- Ferroptosis-Related Immune Genes in Hematological Diagnosis of Parkinson's Diseases.Molecular neurobiology · 2023Article
- Clinical trials for cognition in Parkinson's disease: Where are we and how can we do better?Parkinsonism & related disorders · 2023Review
- Impact of the Dopamine System on Long-Term Cognitive Impairment in Parkinson Disease: An Exploratory Study.Movement disorders clinical practice · 2023Article
- Identification of immune signatures in Parkinson's disease based on co-expression networks.Frontiers in genetics · 2023Article
- Outcome Measures for Disease-Modifying Trials in Parkinson's Disease: Consensus Paper by the EJS ACT-PD Multi-Arm Multi-Stage Trial Initiative.Journal of Parkinson's disease · 2023Article
- Identifying key multi-modal predictors of incipient dementia in Parkinson's disease: a machine learning analysis and Tree SHAP interpretation.Frontiers in aging neuroscience · 2023Article
- A task-specific cognitive domain decline is correlated with plasma and neuroimaging markers in patients with Parkinson's disease.Journal of neurology · 2022Article
- Machine learning-based characterization of cuprotosis-related biomarkers and immune infiltration in Parkinson's disease.Frontiers in genetics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Dementia in Parkinson's disease affects 50% of patients within 10 years of diagnosis but there is wide variation in severity and timing. Thus, robust neuroimaging prediction of cognitive involvement in Parkinson's disease is important: (i) to identify at-risk individuals for clinical trials of potential new treatments; (ii) to provide reliable prognostic information for individuals and populations; and (iii) to shed light on the pathophysiological processes underpinning Parkinson's disease dementia. To date, neuroimaging has not made major contributions to predicting cognitive involvement in Parkinson's disease. This is perhaps unsurprising considering conventional methods rely on macroscopic measures of topographically distributed neurodegeneration, a relatively late event in Parkinson's dementia. However, new technologies are now emerging that could provide important insights through detection of other potentially relevant processes. For example, novel MRI approaches can quantify magnetic susceptibility as a surrogate for tissue iron content, and increasingly powerful mathematical approaches can characterize the topology of brain networks at the systems level. Here, we present an up-to-date overview of the growing role of neuroimaging in predicting dementia in Parkinson's disease. We discuss the most relevant findings to date, and consider the potential of emerging technologies to detect the earliest signs of cognitive involvement in Parkinson's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.